Brent Norton

Venture Partner, Lumira Ventures

Role: Associate

Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin

Streams: Advanced Therapies, Artificial Intelligence, Cancer

Dr. Brent Norton is an accomplished business leader with operational and directorial experience across several successful enterprises which have achieved significant product sales, returns for investors and positively impacted hundreds of thousands of lives. He uses his cross functional knowledge to develop strategy, raise capital and build important relationships in the academic and business community. Dr. Norton founded PreMD, completing an IPO and listings on the TSX and AMEX. Operationally, he built R&D and commercial operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal, etc., and has taken products through the FDA to global out-licensing with J&J. He was a founding director of Novadaq, which was sold to Stryker. In 2020 Dr. Norton was named to the board of directors on the Finance, Risk & Audit and Research & Innovation Committee of the Association of Faculties of Medicine of Canada. The AFMC represents Canada’s 17 faculties of medicine and is the voice of academic medicine in Canada.

Having completed his MD,CM at McGill University, Dr. Norton subsequently obtained an MBA at the University of Western Ontario’s Richard Ivey School of Business and is a certified director from the Institute of Corporate Directors. He has been an active member of several boards of directors, public and private, in both Canada and the US, and an active volunteer. His involvement on boards has commonly been extended to working with the founders or CEO’s through a significant inflection point or the commercial validation and monetization of one or more of the company’s assets. Dr. Norton is a director and chair of Tetra Bio-Pharma, a director of Ortho RTI, and a CDL Associate.